| Application(s)/Product(s) | Company | Status | Condition | Nanocomponent | Targeting Mechanism |
|---|---|---|---|---|---|
| Ontak [45,46] | Seragen, Inc. | Approved (1999) | T-Cell Lymphoma | Protein Nanoparticle | IL-2 Protein |
| MBP-Y003, MBP-Y004, MBP-Y005 [47] | Mebiopharm Co., Ltd | Preclinical | Lymphoma | Liposome | Transferrin |
| MBP-426 [47–49] | Mebiopharm Co., Ltd | Phase I/II | Solid Tumors | Liposome | Transferrin |
| CALAA-01 [19,50] | Calando Pharmaceuticals | Phase I | Solid Tumors | Nanoparticle | Transferrin |
| SGT-53 [19,51] | SynerGene Therapeutics, Inc. | Phase I | Solid Tumors | Liposome | Transferrin |
| MCC-465 [48,52] | Mitsubishi Tanabe Pharma Corp | Phase I | Stomach Cancer | Liposome | GAH Antibody |
| Actinium-225-HuM195 [53] | National Cancer Institute | Phase I | Leukemia | Nanoparticle | HuM195 Antibody |
| AS15 [54] | GlaxoSmithKline Biologicals | Phase I/II | Metastatic Breast Cancer | Liposome | dHER2 Antibody |
| PK2 [48,55] | Pharmacia & Upjohn Inc. | Phase I | Liver Cancer | Polymeric Nanoparticle | Galactose |
| Rexin-G, Reximmune-C [56,57] | Epeius Biotechnologies | Phase I/II | Solid Tumors | Nanoparticle | von Willebrand factor (Collagen-Binding) |
| Aurimune (CYT-6091) [19,58] Auritol (CYT-21001) [59] |
CytImmune Sciences, Inc. | Phase II Preclinical | Solid Tumors | Colloid Gold | TNF-α |
| SapC-DOPS[60,61] | Bexion Pharmaceuticals, Inc. | Preclinical | Solid Tumors | Liposome | Saposin C |
| Targeted Emulsions [62,63] | Kereos, Inc. | Preclinical | In Vivo Imaging | Emulsion | "Ligands" |
| Opaxio [42,64] | Cell Therapeutics, Inc. | Phase III | Solid Tumors | Polymeric Nanoparticle | Enzyme-Activated |
| ThermoDox [43] | Celsion Corporation | Phase II/III | Solid Tumors | Liposome | Thermosensitive |
| DM-CHOC-PEN [44,65] | DEKK-TEC, Inc. | Phase I | Brain Neoplasms | Emulsion | Penetrate Blood-Brain-Barrier |